TCR2 Therapeutics Inc. (TCRR)

NASDAQ: TCRR · IEX Real-Time Price · USD
2.94
+0.05 (1.73%)
At close: Jul 5, 2022 4:00 PM
3.00
+0.06 (2.04%)
After-hours: Jul 5, 2022 6:46 PM EDT

Income Statement (Annual)

Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year 202120202019201820172016
Selling, General & Admin
22.516.7213.896.783.612.26
Research & Development
77.2451.9837.4919.679.577.67
Other Operating Expenses
00000-0.02
Operating Expenses
99.7468.751.3826.4513.189.92
Operating Income
-99.74-68.7-51.38-26.45-13.18-9.92
Other Expense / Income
-0.22-1.74-3.89-2.2-0.110
Pretax Income
-99.52-66.96-47.5-24.25-13.07-9.92
Income Tax
0.290.160.1000
Net Income
-99.81-67.12-47.6-24.25-13.07-9.92
Preferred Dividends
0049.937.31.790.79
Net Income Common
-99.81-67.12-97.5-61.55-14.86-10.7
Shares Outstanding (Basic)
382821100
Shares Outstanding (Diluted)
382821100
Shares Change
35.53%32.63%3278.52%67.87%34.35%-
EPS (Basic)
-2.63-2.40-4.62-98.53-39.94-38.64
EPS (Diluted)
-2.63-2.40-4.62-98.53-39.94-38.64
Free Cash Flow Per Share
-2.45-2.28-2.14-31.63-33.33-37.00
Effective Tax Rate
-0.29%-0.24%-0.21%0.00%0.00%0.00%
EBITDA
-96.69-65.37-46.64-23.83-12.77-9.7
Depreciation & Amortization
2.831.590.860.420.30.22
EBIT
-99.52-66.96-47.5-24.25-13.07-9.92
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).